Triple-negative Breast Cancer
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-10-24Clinical Trial Update: STEMVAC in Patients With Early Stage Triple Negative Breast Cancer [Phase 2]
STEMVAC is being studied in a Phase 2 trial for early-stage triple-negative breast cancer. The study is currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-10-22Clinical Trial Update: Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients [Phase 2]
Phase 2 clinical trial evaluating anthracycline-free neoadjuvant chemoimmunotherapy for triple-negative breast cancer is currently recruitin…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) [Phase 1]
First-in-human Phase 1 study of DS-1062a for advanced solid tumors, including breast cancer subtypes and non-small cell lung cancer, is unde…
-
CLINICAL_TRIALS research · 2025-10-20Clinical Trial Update: A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial update describing safety, tolerability, and imaging with [68Ga]Ga-DPI-4452 and safety, tolerability, and efficacy…
-
CLINICAL_TRIALS research · 2025-10-16Clinical Trial Update: Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas [Phase 1, Phase 2]
Clinical trial update describing a Phase 1/2 study of the monoclonal antibody IMT-009 in various advanced solid tumors and lymphomas, with t…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Sacituzumab Govitecan In TNBC [Phase 2]
Phase 2 study of Sacituzumab Govitecan in triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies [Phase 1]
A Phase 1 study of JANX008 in advanced or metastatic solid tumors is currently recruiting, evaluating multiple indications including Non-Sma…
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) [Phase 2]
Phase 2 clinical trial update evaluating preoperative pembrolizumab plus radiation therapy in breast cancer, including triple-negative and H…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC [Phase 2]
A Phase 2 clinical trial investigating neoadjuvant tumor-infiltrating lymphocyte (TIL)– and response-adapted chemoimmunotherapy for triple-n…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors [Phase 2]
Phase 2 clinical trial evaluating atezolizumab in combination with BDB001 and immunogenic radiotherapy for advanced solid tumors is currentl…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
A ClinicalTrials.gov registry entry for NCT02302742 describes a germline mutation carrier registry focused on triple-negative breast cancer …
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) [Phase 1, Phase 2]
This document provides an update on a phase 1/2 trial evaluating cisplatin plus romidepsin and nivolumab for locally recurrent or metastatic…
-
CLINICAL_TRIALS research · 2025-10-02Clinical Trial Update: Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial is evaluating infusion of NY-ESO-1–specific TCR-engineered lymphocytes in patients with NY-ESO-1-expressing…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer [Phase 1]
This update notes an ongoing Phase 1 trial evaluating PVX-410 vaccine with pembrolizumab in patients with HLA-A2+ metastatic triple-negative…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer [Phase 2]
This Phase 2 trial update describes investigating the combination of radiation therapy, an immunotherapy agent, and a PARP inhibitor for tri…
-
CLINICAL_TRIALS research · 2025-10-01Clinical Trial Update: A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) [Phase 2]
This is a Phase II, single-center trial evaluating sacituzumab govitecan in combination with pembrolizumab as neoadjuvant therapy for Stage …
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients [Phase 1]
Phase I trial evaluating Niraparib given concurrently with postoperative radiotherapy in patients with triple-negative breast cancer.
-
CLINICAL_TRIALS research · 2025-09-26Clinical Trial Update: A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors [Phase 1]
This is a Phase 1 clinical trial update for BL-M02D1 in patients with locally advanced or metastatic triple-negative breast cancer and other…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases [Phase 2]
Phase II trial assessing Dato-DXd in triple-negative breast cancer patients with newly diagnosed or progressing brain metastases is currentl…
-
CLINICAL_TRIALS research · 2025-09-24Clinical Trial Update: A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
Clinical trial update on Invikafusp alfa in combination with sacituzumab govitecan in adults with advanced solid tumors, including triple-ne…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel [NA]
Clinical trial update describing a neoadjuvant regimen for early high-risk triple-negative breast cancer in HRD-positive tumors using a comb…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer [Phase 3]
A Phase III clinical trial evaluating ESG401 for unresectable recurrent or metastatic triple-negative breast cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC [Phase 2]
A phase 2 clinical trial at Johns Hopkins is evaluating PET-guided, response-adapted neoadjuvant therapy for triple-negative breast cancer a…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) [NA]
The document reports the completion of a study to develop a patient communication tool (HECTOR) for discussing cancer treatment resistance, …
-
CLINICAL_TRIALS research · 2025-09-18Clinical Trial Update: Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer [Phase 3]
A Phase 3 trial compares sacituzumab govitecan-hziy plus pembrolizumab against physician's choice plus pembrolizumab in previously untreated…